If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.00
Bid: 20.00
Ask: 22.00
Change: 0.00 (0.00%)
Spread: 2.00 (10.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 21.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

Thu, 04th Jan 2024 10:43

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Angle PLC, up 62% at 21.50 pence, 12-month range 9.07p-48.50p. Shares in the medical diagnostics firm soar after it unveils "breakthrough" clinical results from DNA molecular analysis of cancer patient blood samples that "provide a unique insight into the progression of each patient's cancer and how this may be treated". Angle says the results "highlight the potential for the Parsortix system to identify key variants [of] DNA mutations missed by other approaches to help guide treatment decisions." Chief Executive Officer Andrew Newland says: "Today's breakthrough is the critical next step post the [US Food & Drug Administration] clearance to show in a sample-to-answer format the potential clinical value of [next generation sequencing] molecular analysis on a repeat basis of living cancer cells harvested from patient blood samples. Angle is committed to delivering transformational benefits to cancer patients through a simple blood test. This is a major step in this process."

----------

Likewise Group PLC, up 15% at 23.00p, 12-month range 14.00p-28.00p. The domestic and commercial floor coverings distributor says 2023 gross sales revenue rose 14% to GBP140.2 million from a year earlier, while sales in Likewise Floors rose 29%. It says these increases are "particularly positive given the macro economic headwinds and subsequent challenging market conditions". Likewise says 2023 sales revenue is ahead of current market expectations and underlying profitability is expected to be in line with market expectations, reflecting the continued investment in the future of the business. Looking ahead, it is confident of achieving current market expectations for 2024, as it "continues to develop its position in the UK flooring market".

----------

AIM - LOSERS

----------

Landore Resources Ltd, down 13% at 2.70p, 12-month range 2.33p-18.37p. The Ontario, Canada-focused precious and base metal project explorer and developer raises GBP600,000 via a placing and subscription of 25.0 million new shares at a price of 2.4p each. The net proceeds of the fundraising will be used for general working capital purposes and to progress its strategy towards advancing its flagship BAM gold project at the Junior Lake property in northwestern Ontario. It says the new shares represent around 17% of its enlarged share capital. Landore also says Chief Executive Officer Claude Lemasson resigns with immediate effect, with Glenn Featherby assuming the role of interim CEO.

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
17 Feb 2020 15:25

Angle upbeat on German research into 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.

Read more
11 Feb 2020 10:51

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Read more
11 Feb 2020 07:41

Angle upbeat on research into Parsortix with melanoma patients

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.

Read more
30 Jan 2020 11:41

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Read more
23 Jan 2020 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
22 Jan 2020 11:00

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Read more
7 Nov 2019 13:50

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Read more
31 Oct 2019 15:38

Angle Submits Positive Test Results For Parsortix System To US FDA

Angle Submits Positive Test Results For Parsortix System To US FDA

Read more
4 Oct 2019 15:17

Angle upbeat on patent grant for prostate cancer blood assessment

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.

Read more
4 Oct 2019 08:58

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Read more
4 Sep 2019 14:09

Angle Reports Positive Study Results For Parsortix System

(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it

Read more
29 Aug 2019 10:57

Angle Ovarian Cancer Testing Platform Study Enrols First Patients

(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study

Read more
29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

Read more
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.